PRIME MEDICINE INC (PRME:NASDAQ)
$3.99 0.41 (11.4525%)
Analysed PRIME MEDICINE INC (PRME:NASDAQ) News Sources
Temporary Weakness in Intellia Stock Seems Like a Buying Opportunity
29-09-2026
barchart.com
Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease
05-10-2026
yahoo.com
Gene Editors, Including Powerhouse Beam Therapeutics, Diverge On Legal Battle
08-07-2026
yahoo.com
Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics
15-07-2026
yahoo.com
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease
23-07-2026
yahoo.com
Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
30-07-2026
yahoo.com
Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates
06-08-2026
yahoo.com
Prime Medicine to Participate in Upcoming Investor Conferences
03-09-2026
yahoo.com
CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
23-09-2026
stocktwits.com
Prime Medicine stock surges on FDA IND clearance
24-09-2026
yahoo.com
What is the current price of PRIME MEDICINE INC (PRME:NASDAQ)?
The current price of PRIME MEDICINE INC (PRME:NASDAQ) is $3.99.
PRIME MEDICINE INC (PRME:NASDAQ) absolute price change since previous trading day?
The absolute price change of PRIME MEDICINE INC (PRME:NASDAQ) since the previous trading day is $0.41.
PRIME MEDICINE INC (PRME:NASDAQ) percentage price change since previous trading day?
The percentage price change of PRIME MEDICINE INC (PRME:NASDAQ) since the previous trading day is 11.4525%.
What is the most recent average sentiment score for PRIME MEDICINE INC (PRME:NASDAQ)?
The most recent average sentiment score for PRIME MEDICINE INC (PRME:NASDAQ) is 63 out of 100.
What is the most recent average sentiment for PRIME MEDICINE INC (PRME:NASDAQ)?
The most recent sentiment for PRIME MEDICINE INC (PRME:NASDAQ) is .
SEC-8K** Filing Available For PRIME MEDICINE INC (PRME:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.